Deer Consumer Products, Inc. (DEER) soars on record 2011 results

Posted on Thursday, March 29th, 2012

Deer Consumer ProductsShares of China-based Deer Consumer Products, Inc. (Nasdaq: DEER) were up as much as 53 percent from Wednesday’s closing price on Thursday after the company reported record 2011 financial results, and a rosy outlook for 2012.

Shares climbed as high as $4.89 on Thursday, up from Wednesday’s closing price of $3.18.

The company reported 2011 revenue of $226.7 million, up 28.9 percent from the previous year. The growth was driven by the company’s sales expansion in the China domestic market for its Deer branded product lines coupled with Deer Consumer Products’ ability to raise the average selling prices of its products, a March 29 press release stated.

Net income for 2011 increased 31 percent to $39.8 million, or $1.18 per share, over the same period last year.

The company also reaffirmed its 2012 financial guidance, and stated that it expects 2012 revenue guidance of between $270 million and $290 million, and net income of between $45 million and $47 million.

Deer’s product mix includes housewares and appliances such as blenders, choppers, food processors, and microwave ovens.

“Deer currently has access to approximately 4,000 retail locations across China and has developed a well-recognized brand by working with various retail channels,” said Deer Consumer Products’ Chairman and CEO Bill He in a March 29 press release. ”We believe China remains the world’s largest and fastest growing consumer retail market and has strong domestic demand for small household appliances. There are approximately 35,000 retail locations across China that Deer could potentially penetrate. Deer has significant growth potential in China.”

Shares of DEER are down roughly 39 percent over the past 12 months, according to historical data provided by Yahoo Finance.

Get Free Breakout Stock Alerts via Email:

Amylin Pharmaceuticals, Inc. (AMLN) soars on news of rejection of Bristol-Myers takeover bid

Posted on Wednesday, March 28th, 2012

Shares of diabetes drug maker Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN) were up more than 50 percent from Tuesday’s closing price in morning trading on Wednesday after Bloomberg reported that Amylin rebuffed an unsolicited takeover bid from pharma giant Bristol-Myers Squib Co. (NYSE: BMY) for $3.5 billion, or $22 a share.

According to data provided by Yahoo Finance, shares of AMLN touched a high of $23.50 on Wednesday, up from Tuesday’s closing price of $15.39.

Reuters reported that Amylin has been considered a possible takeover target for quite some time. Spokeswomen for Bristol-Myers and Amylin refused to comment, Reuters reported.

Bristol Myers Squibb BMY“Bristol as an acquirer makes sense,” Robyn Karnauskas, an analyst with Deutsche Bank in New York, wrote in a note to clients today, Bloomberg reported. “Amylin could be worth up to $31 a share based on expense synergies. However, Bristol is financially disciplined.”

There have been 16 acquisitions more than $1 billion of biotech companies in Amylin’s peer group in the past five years, according to data compiled by Bloomberg. The average disclosed size was $8 billion, with an average premium of 35 percent, the Bloomberg data show.

 

Get Free Breakout Stock Alerts via Email:

Chelsea Therapeutics International Ltd. (CHTP) rises on FDA nod for Northera

Posted on Friday, February 24th, 2012

Chelsea Therapeutics CHTPShares of Charlotte-based drug maker, Chelsea Therapeutics International Ltd. (Nasdaq: CHTP) were up as much as 69 percent from Thursday’s closing price on Friday after it was announced that the U.S. Food and Drug Administration voted in favor of recommending Chelsea’s neurological drug, Northera, for approval.

Chelsea Therapeutics shares touched a high of $4.09 on Friday, up from Thursday’s closing price of $2.41.

“We believe our clinical data demonstrates the significant symptomatic benefit of Northera treatment across a broad range of Neurogenic OH symptoms,” said Chelsea Therapeutics’ CEO Dr. Simon Pedder in a statement. “Since no other treatment has been proven to alleviate the symptoms of neurogenic OH or improve patients’ ability to carry out activities of daily living, we continue to believe Northera could fill this unmet need for patients with Parkinson’s disease, MSA, PAF and other neurologic diseases. We are pleased by today’s panel vote and we look forward to continuing to work with the FDA in advance of the March 28, 2012 PDUFA action date.”

Northera is the lead investigational agent in Chelsea’s pipeline, and has has been studied in two Phase III clinical trials for the treatment of symptomatic neurogenic orthostatic hypotension in patients with primary autonomic failure — a group of diseases that includes Parkinson’s disease, multiple system atrophy (MSA) and pure autonomic failure (PAF). Droxidopa is a synthetic catecholamine that is directly converted to norepinephrine (NE) via decarboxylation, resulting in increased levels of NE in the nervous system, both centrally and peripherally.

Chlesea Therapeutics submitted a New Drug Application (NDA) for Northera in September 2011. The drug was previously granted Orphan Drug Designation, which is granted by the FDA to treatments for rare diseases and disorders.

 

Get Free Breakout Stock Alerts via Email:

Vringo Inc VRNG surges on news of new technology for Nokia, Facebook

Posted on Tuesday, January 31st, 2012

Vringo Inc VRNG surges on newsShares of software provider Vringo Inc (AMEX: VRNG) were up as much as 35% from Mondays closing price of 1.16 after the company announced it has released a new version of Facetones™ customized for the latest mobile devices released by Nokia.

The Facetones app is integrated with Facebook and generates an automatic, visually exciting slideshow of photos displaying your friend’s face and other social content each time you communicate with that friend using your mobile device.  With Vringo’s latest version of Facetones , the application is now fully optimized for Nokia’s Symbian^3 operating system.

The free ad supported app has been a viral hit for Vringo and is closing in on one million downloads. VRNG monetizes this app using Google’s Admob mobile advertising service and it is currently generating 800,000- 900,000 ad impressions per day.

About Vringo

Vringo (AMEX: VRNG) is a provider of software platforms for mobile social and video applications. With its award-winning video ringtone application and other mobile software platforms – including Facetones™, Video Remix and Fan Loyalty – Vringo transforms the basic act of making and receiving mobile phone calls into a highly visual, social experience. Vringo’s video ringtone service enables users to create or take video, images and slideshows from virtually anywhere and turn it into their visual call signature. In a first for the mobile industry, Vringo has introduced its patented VringForward technology, which allows users to share video clips with friends with a simple call.  Vringo’s Facetones™ application creates an automated video slideshow using friends’ photos from social media web sites, which is played each time a user communicates with a friend using a mobile device. Vringo’s Video ReMix application, in partnership with music artists and brands, allows users to create their own music video by tapping on a Smartphone or tablet.  Lastly, Fan Loyalty is a platform that lets users interact, vote and communicate with contestants in reality TV series that it partners with, as well as downloading and setting clips from such shows as video ringtones. Vringo’s video ringtone application has been heralded by The New York Times as “the next big thing in ringtones” and USA Today said it has “to be seen to be believed.” For more information, visit: www.vringo.com

Get Free Breakout Stock Alerts via Email:

Caterpillar Inc CAT profits soars to 60 percent

Posted on Thursday, January 26th, 2012

Caterpillar Inc CAT Caterpillar Inc. (NYSE: CATreported a 60 percent rise in quarterly earnings that exceeded Wall Street expectations on record sales of construction and mining equipment, and projected growth for 2011. Fourth-quarter sales and revenues in 2011 were an all-time quarterly record at $17.243 billion, an increase of 35 percent compared with $12.807 billion in the fourth quarter of 2010. Fourth-quarter profit was $1.547 billion compared with $968 million in the fourth quarter of 2010. Profit of $2.32 per share was 58 percent higher than the $1.47 per share in the fourth quarter of 2010.

The growth of Caterpiller is a positive indicator in the strength of the global economy and in construction spending in the United States. Caterpillar credits the incredible growth to many of its customers replacing aging equipment and rapid growth in developing parts of the world.

“Our strategy is squarely focused on customers, and in 2011 our employees, suppliers and dealers delivered. We improved product quality, invested significantly in manufacturing capacity and product  development, and improved our market position.” said Caterpillar Chairman and Chief Executive Officer Doug Oberhelman.

About Caterpillar Inc. (NYSE: CAT)

Caterpillar Inc. is a corporation which designs, manufactures, markets and sells machinery and engines and sells financial products and insurance to customers via a worldwide dealer network. Caterpillar is the world’s largest manufacturer of construction and mining equipment, diesel and natural gas engines and industrial gas turbines.  With more than US$70 billion in assets, Caterpillar was ranked number one in its industry and number 44 overall in the 2009 Fortune 500. Caterpillar stock is a component of the Dow Jones Industrial Average.

Get Free Breakout Stock Alerts via Email: